|
|
The
Charing Cross Hospital experience with temozolomide in patients with gliomas
Newlands ES, O'Reilly SM, Glaser MG, Bower M, Evans H, Brock C, Brampton MH,
Colquhoun I, Lewis P, Rice-Edwards JM, Illingworth RD, Richards PG
Department of Medical Oncology, Charing Cross Hospital, London,
U.K
Temozolomide, a new oral cytotoxic agent, was given to 75 patients with
malignant gliomas.
The schedule used was for the first course 150 mg/m2 per day for 5 days (i.e.
total dose 750 mg/m2), escalating, if no significant myelosuppression was noted
on day 22, to 200 mg/m2 per day for 5 days (i.e. total dose 1000 mg/m2) for
subsequent courses at 4-week intervals.
There were 27 patients with primary disease treated with two courses of
temozolomide prior to their radiotherapy and 8 (30%) fulfilled the criteria for
an objective response.
There were 48 patients whose disease recurred after their initial surgery and
radiotherapy and 12 (25%) fulfilled the criteria for an objective
response.
This gave an overall objective response rate of 20 (27%) out of 75
patients.
Temozolomide was generally well tolerated, with little subjective toxicity and
predictable myelosuppression.
However, the responses induced with this schedule were of short duration and had
relatively little impact on overall survival.
In conclusion, temozolomide given in this schedule has activity against high
grade glioma.
However, studies evaluating chemotherapy in primary brain tumours should include
a quality-of-life/performance status evaluation in addition to CT or MRI
scanning assessment.
PMID: 9038604 [PubMed - indexed for
MEDLINE]
Source:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9038604&dopt=Abstract
|
